The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies.
Tian G, Zhao X, Nie J, Dai L, Hu W, Zhang J, Chen X, Han J, Ma X, Wu D, Han S, Long J, Wang Y, Zhang Z, Fang J.
Tian G, et al.
J Thorac Dis. 2022 Jun;14(6):2201-2212. doi: 10.21037/jtd-22-622.
J Thorac Dis. 2022.
PMID: 35813748
Free PMC article.